Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Middle–Down, and De Novo Bottom–Up Mass Spectrometry
Molecular & Cellular Proteomics · 2025-11 · 24 (11) · 101088
DOI: 10.1016/j.mcpro.2025.101088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2025-11. Verfasst von Lei Xin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics Solutions Inc., Waterloo, Ontario, Canada. Hauptthemen laut MEDLINE: Mass Spectrometry, Antibodies, Sequence Analysis, Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Polyclonal antibodies (pAbs) represent nature's approach to robust immunity, targeting multiple sites on pathogens, but their complex mixtures have remained largely unsequenceable, limiting their therapeutic potential. While monoclonal antibodies (mAbs) dominate therapeutics because of their reproducibility, pAbs offer superior resilience against viral mutations and broader target recognition. Current pAb sequencing attempts have shown limitations, requiring germline databases or B-cell sequencing. Due to the highly variable nature of antibodies, as well as the possibility of unavailable B cells, there is a need for a purely mass spectrometry- and de novo sequencing-based solution. Here, we present PolySeq.AI, an automated de novo workflow that combines bottom-up, middle-down, and intact mass analysis, to accurately sequence pAb samples without relying on external databases. PolySeq.AI achieved >99% sequencing accuracy across all tested samples, including an mAb mixture from the HB-95 cell line and a mixture of four mAbs, with complete bottom-up coverage and strong middle-down fragment support. Importantly, recombinant antibodies produced from our de novo sequences of HB-95 antibodies retained full binding capabilities to human leukocyte antigen-I complexes, confirming the accuracy and efficacy of our pAb de novo sequencing workflow.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioinformatics Solutions Inc., Waterloo, Ontario, Canada.
- Bioinformatics Solutions Inc., Waterloo, Ontario, Canada; BaizhenBio Inc., Wuhan, China.
- Central China Institute of Artificial Intelligence, Zhengzhou, China; Bioinformatics Solutions Inc., Waterloo, Ontario, Canada.
- BaizhenBio Inc., Wuhan, China.
- Central China Institute of Artificial Intelligence, Zhengzhou, China; David R. Cheriton School of Computer Science, University of Waterloo, Ontario, Canada. Electronic address: mli@uwaterloo.ca.
- Bioinformatics Solutions Inc., Waterloo, Ontario, Canada. Electronic address: bshan@bioinfor.com.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Xin, L., Li, W., Zhang, S., Tran, N. H., Chen, Z., Ma, J., Peng, C., Aihemaiti, A., Hoffman, K., Zhang, X., Sun, W., Li, L., Wang, Z., Li, M., & Shan, B. (2025). Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Middle–Down, and De Novo Bottom–Up Mass Spectrometry. Molecular & Cellular Proteomics, 24(11), 101088. https://doi.org/10.1016/j.mcpro.2025.101088
Vancouver
Xin L, Li W, Zhang S, Tran NH, Chen Z, Ma J, et al. Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Middle–Down, and De Novo Bottom–Up Mass Spectrometry. Molecular & Cellular Proteomics. 2025;24(11):101088. doi:10.1016/j.mcpro.2025.101088
BibTeX
@article{Xin2025,
author = {Xin, Lei and Li, Wenting and Zhang, Shuyang and Tran, Ngoc Hieu and Chen, Zheng and Ma, Jun and Peng, Chao and Aihemaiti, Ailee and Hoffman, Kyle and Zhang, Xiyue and Sun, Weiping and Li, Linting and Wang, Zihao and Li, Ming and Shan, Baozhen},
title = {Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Middle–Down, and De Novo Bottom–Up Mass Spectrometry},
journal = {Molecular & Cellular Proteomics},
year = {2025},
volume = {24},
number = {11},
pages = {101088},
doi = {10.1016/j.mcpro.2025.101088}
}
EUVIMED